English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/213428
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild‐moderate fibrosis: Results from a real‐world cohort

AuthorsPuigvehí, Marc; Cuenca, Beatriz de; Viu, Ana; Diago, Moisés; Turnes, Juan; Gea, Francisco; Pascasio, Juan Manuel; Lens, Sabela; Cabezas González, Joaquín; Badía, Ester; Olveira, Antonio; Morillas, Rosa María; Torras, Xavier CSIC ORCID ; Montoliu, Silvia; Cordero, Patricia; Castro Urda, José L.; Salmerón, Javier; Molina, Esther; Sánchez‐Ruano, Juan J.; Moreno, Javier CSIC ORCID; Antón, María D.; Moreno, José M.; Vega, Juan de la; Calleja, José Luis; Carrión, José A.
KeywordsDasabuvir
Ombitasvir
Paritaprevir
Sustained virological response
Issue DateJan-2019
PublisherJohn Wiley & Sons
CitationLiver International 39(1): 90-97 (2019)
Abstract[Background & Aims] The interferon‐free regimen paritaprevir/ritonavir, ombitasvir + dasabuvir (PTV /r/OBV /DSV ) has shown high efficacy in patients with hepatitis C virus (HCV ) genotype 1b infection when administered for 8 or 12 weeks, but data regarding the 8‐week treatment are scarce. The aim of our study was to assess the efficacy and safety of the 8‐week administration of PTV /r/OBV /DSV in a real‐world cohort.
[Methods] We performed a multicentre observational study from Spanish Hepa‐C database including patients receiving 8 weeks of PTV /r/OBV /DSV (October 2016‐November 2017). Those with advanced fibrosis, with non‐genotype 1b or who were treatment‐experienced were excluded.
[Results] A total of 211 patients were registered from 23 Spanish centres; eleven were excluded. At baseline, 42.5% (n = 85) were male, median (range) age was 57 (23‐86), ALT was 45 (11‐494) IU/mL, viral load was 6.1 (3.3‐8.2) log10 IU/mL, and 74.5% had mild liver fibrosis (F0‐F1) and 25.5% moderate fibrosis (F2). At the end of treatment (EOT ), HCV viral load was undetectable in 100% (200/200). Seven patients relapsed after treatment discontinuation. Sustained virological response (SVR 12) rates by intention‐to‐treat analysis were 96% (192/200). Regarding treatment safety, 2 patients developed ALT elevation >5x ULN, but there were no treatment discontinuations. One patient died 7 weeks after EOT.
[Conclusion] Treatment with PTV/r/OBV/DSV in genotype 1b‐infected treatment‐naive patients with mild‐moderate fibrosis shows excellent efficacy and safety in real life, similarly to clinical trials. Clinicaltrials.gov, number: NCT 03122132.
Publisher version (URL)https://doi.org/10.1111/liv.13950
URIhttp://hdl.handle.net/10261/213428
DOIhttp://dx.doi.org/10.1111/liv.13950
ISSN1478-3223
E-ISSN1478-3231
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.